Pharmaceutical News

RSS

Permanent atrial fibrillation twins risk of stroke than paroxysmal AF

Permanent atrial fibrillation (AF) doubles the risk of stroke compared to paroxysmal AF, according to research in more than 6 000 patients presented at ESC Congress today by Dr Thomas Vanassche from Belgium. The findings suggest that a simple clinical assessment of the type of AF can help doctors to better estimate stroke risk.

2 Sep 2014

Serelaxin reduces occurrence of in-hospital worsening heart failure

Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. The results were presented for the first time today at ESC Congress by co-principal investigator Professor John R. Teerlink.

1 Sep 2014

New polypill increases adherence to treatment following myocardial infarction

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014 today by principal investigator Dr Valentin Fuster, director of Mount Sinai Heart in New York, US.

1 Sep 2014

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule.

1 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

Darapladib drug fails to reduce risk of recurrent major coronary events

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent major coronary events, according to a study published by JAMA.

1 Sep 2014

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration.

1 Sep 2014

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.

30 Aug 2014

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

FK506 possesses a well-studied neuroregenerative effect, stimulating neurite extension in the presence of nerve growth factor in vitro, and enhancing nerve regeneration following nerve crush injury and isografting.

30 Aug 2014

$Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis$

Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis

Raloxifene is a U.S. Food and Drug Administration (FDA)-approved treatment for decreasing fracture risk in osteoporosis.

30 Aug 2014

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN.

29 Aug 2014

Vasopressin more effective for cardiopulmonary resuscitation

Epinephrine has been shown to be a first-choice drug for cardiopulmonary resuscitation. Nevertheless, its β-adrenergic effect probably increases myocardial oxygen consumption and leads to severe cardiac and cerebral injuries; moreover, epinephrine does not elevate long-term survival rates.

29 Aug 2014

Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

29 Aug 2014

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

28 Aug 2014

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

Mylan Inc. today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration.

28 Aug 2014

Study: Many HIV infected African-Americans may not be receiving effective doses of maraviroc drug

Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study from Johns Hopkins suggests. The initial dosing studies, completed before the drug was licensed in 2007, included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body.

28 Aug 2014

THC may slow or halt progression of Alzheimer's disease

Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer's disease, a recent study from neuroscientists at the University of South Florida shows.

28 Aug 2014

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).

28 Aug 2014

TWi Pharmaceuticals obtains final approval from FDA for megestrol acetate 125mg/ml oral suspension

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for megestrol acetate 125mg/ml oral suspension, the generic equivalent to Par Pharmaceutical's Megace ES.

28 Aug 2014

Expanding age of eligibility for measles vaccination could have large effects on coverage in Africa

Expanding the age of eligibility for measles vaccination from 12 to 15 months could have potentially large effects on coverage in Africa, according to a new report published by Princeton University's Woodrow Wilson School of Public and International Affairs.

27 Aug 2014

Pharmaceutical News

Permanent atrial fibrillation twins risk of stroke than paroxysmal AF

Serelaxin reduces occurrence of in-hospital worsening heart failure

New polypill increases adherence to treatment following myocardial infarction

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Darapladib drug fails to reduce risk of recurrent major coronary events

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis

InnoPharma receives FDA approval for generic DACOGEN

Vasopressin more effective for cardiopulmonary resuscitation

Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

Study: Many HIV infected African-Americans may not be receiving effective doses of maraviroc drug

THC may slow or halt progression of Alzheimer's disease

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

TWi Pharmaceuticals obtains final approval from FDA for megestrol acetate 125mg/ml oral suspension

Expanding age of eligibility for measles vaccination could have large effects on coverage in Africa

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News